Study of Her2/neu expression in 100 cases of uterine and cervical carcinoma as a prognostic marker
Keywords:
Her2/neu, uterine carcinoma, cervical carcinoma
Abstract
Background: HER-2/neu, is a gene localized on chromosome 17q21 that encodes a growth factor receptor like molecule with tyrosine- kinase activity. Its expression has been detected in several human cancers and is believed potential. Aim of our study was to evaluate the expression of Her-2/neu oncogene in uterine & cervical carcinomas and determine its correlation with histological type of malignancy, grade and clinical stage of presentation.Methods:Total 100 cases were studied, out of which there was 22 cases of uterine tumour and 78 cases of cervical tumours. The specimens were processed routinely ,stained with standard H&E method and relevant panel of immunohistochemical antibodies were applied (PAP -peroxidase anti- peroxidase method )after thorough histopathological analysis.Result: Her-2/neu was expressed by 3 (13.6%) out of 22 cases of uterine adenocarcinomas while in cases of cervical carcinomas 9 (11.53%)1 out of 78 cases express Her-2neu . In cervical carcinoma, 50% cases of squamous cell carcinomas, 20% poorly differentiated carcinomas, 18.1% well differentiated carcinomas and 3.4% of moderately differentiated carcinomas express Her-2/neu positivity.Conclusion: We have found that Her-2/neu can be used as a prognostic marker in uterine carcinoma and its expression increases with increase in stage and grade of endometrial adenocarcinoma. Her2/ neu has little utility in cervical carcinomas and is not correlated with its grading and staging.References
1) Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholdar S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890-907
2) Gehring PA, Cantrell LA, Shafer A, Abaid LN, Mendivil A, Boggress JF. What is the optimal minimally invasive surgical procedure for endometrial cancer staging in the obese and morbidly obese women?. Gynecol Oncol. 2008:111;4-45
3) Solimen PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, Burke TW, Lu KH. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005:105:575-580
4) Nevin J. Laing D, kaye P, MuCulloch T, Barnard R, Silcocks P, et al. The significance of Erb – b2 immunostaining in cervical cancer. Gynecol Oncol 1999:73:35 4-8.
5) Brunelli M, Manfrin E, Martignoni G, Bersani S, Remo A, Reghellin D, et al. HER-2/neu assessment in breast cancer using the original FDA and New ASCO/CAP guideline recommendations. Impact on selecting patients for Herceptin therapy. Am J Clin Pathol 2008;129;907-11
6) Rose PG: Endometrial carcinoma. N Engl J Med. 1996; 335:640-649.
7) Uzoigwe S.,Seleye Fubara D.; Cancers of uterine cervix in port Harcourt, River state-a 13 year clinicopathological review; Niger J Med.2004 Apr-Jun;13(2):110-3.
8) Clement PB: Pathology of the uterine corpus. Hum Pathol 1991; 22:776-791.
9) Smedts F, Ramaekers F, Troyanovsky S, Pruszczynski M, Robben H, Lane B, Leigh I, Plantema F, Vooijs P: Basal-cell keratins in cervical reserve cells and a comparison to their expression in cervical intraepithelial neoplasia. Am J Pathol 1992; 140:601-61
10) Tavassoli F.A, Devilee P. (Eds.): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. I ARC Press: Lyon 2003:4;698-702.
11) Gupta N, Singh S, Marwah N, Kumar S, Chabra S, Sen R et al. HER-2/ neu expression in lesions of uterine cervix: Is it reliable and consistent?. Indian Journal of pathology and microbiology 2009;52(4):482
12) Mitra AB, Murty VV, Pratap M, Sodhani P, Chaganti RS. EBBB2 (HER-2/neu) oncogene is frequently amplified in squamous cell carcinoma ofuterine cervix. Cancer Res 1999;54:637-9.
13) Berchuck A, Rodriguez G, Kamel A, Soper JT, Clarke-Pearson DL, Bast RC Jr. Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva and vagina. Obstet Gynecol1990;76:381-7
14) Rosty C, Couturier J, Vincent-Salomon A, Genin P, Fréneaux P,Sigal-Zafrani B, et al. Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix. Int J Gynecol Pathol 2004;23:13-7.
15) Califano D, Losito S, Pisano C, Santelli G, Greggi S, Iodice F, et al.Significance of erb-B2 immunoreactivity in cervical cancer. Front Biosci 2006;1:2071-6.
16) Tsuda H, Hirohashi S, Shimosato Y, Tanaka Y, Hirota T, Tsugane S, et al.Immunohistochemical study on over expression of C-erb B2 protein in human breast cancer.Its correlation with gene amplification and long term survival of patients. Jpn J Cancer Res 1990;81:327-32.
17) Lora Ellenson . Brigitte M . Robert A . Richard J.Robert J. K. Endometrial Carcinoma.in Kumar R, Ellienson L, Bonnett B. Blausteins pathology of female genital tract: Vol-6, springer, New York 2012;400-403.
18) Lee.S, Kim. Hyung, Jung J, Lee min, Park C. Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erb B – 2 protein.Gynecologic ocology june 2002;V 85(3): 469-75.
19) Rolitsky CD, Theil K S, Mc Gaughy VR, Copeland LJ, Niemann TH.; Her-2/neu amplification and overexpression in endometrial carcinoma; Int J Gynecol Pathol1999; Apr;18(2);138-43.
20) Nevin J, Laing D, Kaye P, McCulloch T, Barnard R, Silcocks P, et al.The significance of Erb-b2 immunostaining in cervical cancer. Gynecol Oncol 1999;73:354-8.
2) Gehring PA, Cantrell LA, Shafer A, Abaid LN, Mendivil A, Boggress JF. What is the optimal minimally invasive surgical procedure for endometrial cancer staging in the obese and morbidly obese women?. Gynecol Oncol. 2008:111;4-45
3) Solimen PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, Burke TW, Lu KH. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005:105:575-580
4) Nevin J. Laing D, kaye P, MuCulloch T, Barnard R, Silcocks P, et al. The significance of Erb – b2 immunostaining in cervical cancer. Gynecol Oncol 1999:73:35 4-8.
5) Brunelli M, Manfrin E, Martignoni G, Bersani S, Remo A, Reghellin D, et al. HER-2/neu assessment in breast cancer using the original FDA and New ASCO/CAP guideline recommendations. Impact on selecting patients for Herceptin therapy. Am J Clin Pathol 2008;129;907-11
6) Rose PG: Endometrial carcinoma. N Engl J Med. 1996; 335:640-649.
7) Uzoigwe S.,Seleye Fubara D.; Cancers of uterine cervix in port Harcourt, River state-a 13 year clinicopathological review; Niger J Med.2004 Apr-Jun;13(2):110-3.
8) Clement PB: Pathology of the uterine corpus. Hum Pathol 1991; 22:776-791.
9) Smedts F, Ramaekers F, Troyanovsky S, Pruszczynski M, Robben H, Lane B, Leigh I, Plantema F, Vooijs P: Basal-cell keratins in cervical reserve cells and a comparison to their expression in cervical intraepithelial neoplasia. Am J Pathol 1992; 140:601-61
10) Tavassoli F.A, Devilee P. (Eds.): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. I ARC Press: Lyon 2003:4;698-702.
11) Gupta N, Singh S, Marwah N, Kumar S, Chabra S, Sen R et al. HER-2/ neu expression in lesions of uterine cervix: Is it reliable and consistent?. Indian Journal of pathology and microbiology 2009;52(4):482
12) Mitra AB, Murty VV, Pratap M, Sodhani P, Chaganti RS. EBBB2 (HER-2/neu) oncogene is frequently amplified in squamous cell carcinoma ofuterine cervix. Cancer Res 1999;54:637-9.
13) Berchuck A, Rodriguez G, Kamel A, Soper JT, Clarke-Pearson DL, Bast RC Jr. Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva and vagina. Obstet Gynecol1990;76:381-7
14) Rosty C, Couturier J, Vincent-Salomon A, Genin P, Fréneaux P,Sigal-Zafrani B, et al. Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix. Int J Gynecol Pathol 2004;23:13-7.
15) Califano D, Losito S, Pisano C, Santelli G, Greggi S, Iodice F, et al.Significance of erb-B2 immunoreactivity in cervical cancer. Front Biosci 2006;1:2071-6.
16) Tsuda H, Hirohashi S, Shimosato Y, Tanaka Y, Hirota T, Tsugane S, et al.Immunohistochemical study on over expression of C-erb B2 protein in human breast cancer.Its correlation with gene amplification and long term survival of patients. Jpn J Cancer Res 1990;81:327-32.
17) Lora Ellenson . Brigitte M . Robert A . Richard J.Robert J. K. Endometrial Carcinoma.in Kumar R, Ellienson L, Bonnett B. Blausteins pathology of female genital tract: Vol-6, springer, New York 2012;400-403.
18) Lee.S, Kim. Hyung, Jung J, Lee min, Park C. Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erb B – 2 protein.Gynecologic ocology june 2002;V 85(3): 469-75.
19) Rolitsky CD, Theil K S, Mc Gaughy VR, Copeland LJ, Niemann TH.; Her-2/neu amplification and overexpression in endometrial carcinoma; Int J Gynecol Pathol1999; Apr;18(2);138-43.
20) Nevin J, Laing D, Kaye P, McCulloch T, Barnard R, Silcocks P, et al.The significance of Erb-b2 immunostaining in cervical cancer. Gynecol Oncol 1999;73:354-8.
Published
2018-02-27
Issue
Section
Original Article
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
